Current developments in lipid-lowering therapy for the patient with chronic kidney disease

被引:0
作者
Burnhope, Emma [1 ]
Green, Darren [2 ]
Kalra, Philip A. [2 ]
Kalra, Paul R. [1 ]
机构
[1] Portsmouth Hosp NHS Trust, Dept Cardiol, Portsmouth, Hants, England
[2] Salford Royal Fdn NHS Trust, Dept Nephrol, Salford, Lancs, England
关键词
cardiovascular; chronic kidney disease; dialysis; lipid; statin; STAGE RENAL-DISEASE; CARDIOVASCULAR RISK-FACTORS; UNITED-KINGDOM HEART; TRANSPLANT RECIPIENTS; CARDIAC OUTCOMES; LDL CHOLESTEROL; SUDDEN-DEATH; METAANALYSIS; SIMVASTATIN; PROTECTION;
D O I
10.2217/CLP.11.61
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiovascular disease is the leading cause of death amongst patients with chronic kidney disease, particularly end-stage disease. Patients with chronic kidney disease commonly exhibit abnormalities of lipid profile, but also atypical cardiovascular risk factors such as arterial stiffness and chronic inflammation. Hence it is unclear whether these patients benefit from lipid-lowering therapy to the same degree as the general population. In this review we discuss evidence on the clinical benefit and safety of lipid-lowering agents for different stages of chronic kidney disease.
引用
收藏
页码:693 / 702
页数:10
相关论文
共 64 条
  • [1] [Anonymous], RISK EST PREV CARD D
  • [2] [Anonymous], CARDIOVASCULAR DIS C
  • [3] [Anonymous], SDF
  • [4] CARDIAC PATHOLOGY IN PATIENTS WITH END-STAGE RENAL-DISEASE MAINTAINED ON HEMODIALYSIS
    ANSARI, A
    KAUPKE, CJ
    VAZIRI, ND
    MILLER, R
    BARBARI, A
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1993, 16 (01) : 31 - 36
  • [5] *ASS PUBL HLTH OBS, CHRON KIDN DIS PREV
  • [6] Dialysis modalities and dyslipidemia
    Attman, PO
    Samuelsson, O
    Johansson, AC
    Moberly, JB
    Alaupovic, P
    [J]. KIDNEY INTERNATIONAL, 2003, 63 : S110 - S112
  • [7] First united kingdom heart and renal protection (UK-HARP-1) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease
    Baigent, C
    Landray, M
    Leaper, C
    Altmann, P
    Armitage, J
    Baxter, A
    Cairns, HS
    Collins, R
    Foley, RN
    Frighi, V
    Kourellias, K
    Ratcliffe, PJ
    Rogerson, M
    Scoble, JE
    Tomson, CRV
    Warwick, G
    Wheeler, DC
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) : 473 - 484
  • [8] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [9] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Baigent, Colin
    Landray, Martin J.
    Reith, Christina
    Emberson, Jonathan
    Wheeler, David C.
    Tomson, Charles
    Wanner, Christoph
    Krane, Vera
    Cass, Alan
    Craig, Jonathan
    Neal, Bruce
    Jiang, Lixin
    Hooi, Lai Seong
    Levin, Adeera
    Agodoa, Lawrence
    Gaziano, Mike
    Kasiske, Bertram
    Walker, Robert
    Massy, Ziad A.
    Feldt-Rasmussen, Bo
    Krairittichai, Udom
    Ophascharoensuk, Vuddidhej
    Fellstrom, Bengt
    Holdaas, Hallvard
    Tesar, Vladimir
    Wiecek, Andrzej
    Grobbee, Diederick
    de Zeeuw, Dick
    Gronhagen-Riska, Carola
    Dasgupta, Tanaji
    Lewis, David
    Herrington, William
    Mafham, Marion
    Majoni, William
    Wallendszus, Karl
    Grimm, Richard
    Pedersen, Terje
    Tobert, Jonathan
    Armitage, Jane
    Baxter, Alex
    Bray, Christopher
    Chen, Yiping
    Chen, Zhengming
    Hill, Michael
    Knott, Carol
    Parish, Sarah
    Simpson, David
    Sleight, Peter
    Young, Alan
    Collins, Rory
    [J]. LANCET, 2011, 377 (9784) : 2181 - 2192
  • [10] Bromberg JS., 2009, AM J TRANSPL, V9, P1